Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development

Abstract

Introduction-Being on the top list of neglected tropical diseases, leishmaniasis has been marked for elimination by 2020. In the light of small armamentarium of drugs and their associated drawbacks, the understanding of pharmacodynamics and/or pharmacokinetics becomes priority to achieve disease elimination and sustaining it.Areas covered-We have looked into pharmacological aspects of existing and emerging drugs for treatment of leishmaniasis. An in depth understanding of pharmacodynamics and pharmacokinetics (PKPD) provides rational for drug designing and optimizing the treatment strategies. It forms a key to prevent the drug resistance and avoid drug associated adverse effects. We have compiled the researches on understanding the PKPD of different anti-leishmanial formulations, that holds hopes for improved and/or effective disease intervention.Expert opinion-Understanding the pharmacological aspect of drug forms the basis for the clinical application of novel drugs. Tailoring drugs dosage and individualized treatment can avoid the adverse events and bridge gap between the in vitro models and their clinical application. An integrated approach, with pragmatic use of technological advances can improve phenotypic screening, physiochemical properties of novel drugs. Concomitantly, this can serve to improve clinical efficacies, reduce incidence of relapse and accelerate the drug discovery/development process for leishmaniasis elimination.

Advances in Understanding Leishmania Pathobiology: What Does RNA-Seq Tell Us?

“…In Leishmania , the comparison of proteomes has been employed to provide a better understanding of the parasite’s life cycle, host–pathogen interactions, protein–protein interactions and drug resistance mechanisms for different Leishmania species ( Capelli-Peixoto et al, 2019 ). Several key candidates for vaccine development have also been identified through proteomics investigations ( Sundar and Singh, 2018 ; Sundar et al, 2019 ).…”

Unraveling the peculiarities and development of novel inhibitors of leishmanial arginyl‐tRNA synthetase

“…The drugs that are currently being practiced (amphotericin, miltefosine, etc.) have demonstrated toxicity and ineffectivity [1]. Hence, it is necessary to include newer targets in developing antileishmanials to counter the limitations posed by these drugs.…”

Nanobiotecnología en El Tratamiento De Leishmania Spp.

“…Por vía oral se ha usado micelas de miltefosina (hexadecilfosfocolina) (Demicheli et al, 2004;Asthana et al, 2013) y anfotericina B cuyo ensamble molecular le provee permeabilidad paracelular, se optimiza así su biodisponibilidad, este sistema de liberación es útil en leishmaniosis visceral y cutánea. Del mismo modo en el tratamiento oral de la leishmaniosis se ha ensayado con nanoportadores biodegradables a base de lecitina de soja (Lec); formulaciones de AmpB lipídicas basadas en mono y diglicéridos con o sin un derivado lipofílico de vitamina E, succinato de d-αtocoferil polietilenglicol 1000; niosomas de itraconazol; y nanococleatos (nanoestructuras en forma de cigarro compuestas de bicapas lipídicas cargadas negativamente unidas por un catión divalente, normalmente calcio) (Zarif, 2005;Wasan et al, 2010;Dorlo et al, 2012;Khazaeli et al, 2014;Javed et al, 2015;Bruni et al, 2017;Sundar et al, 2019).…”